# Adjuvant Cisplatin Plus Gemcitabine in Operable Cholangiocellular Carcinoma.

> **NCT01073839** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of Zurich** · enrollment: 33 (actual)

## Conditions studied

- Cholangiocellular Carcinoma

## Interventions

- **DRUG:** Cisplatin and Gemcitabine

## Key facts

- **NCT ID:** NCT01073839
- **Lead sponsor:** University of Zurich
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08
- **Primary completion:** 2015-08
- **Final completion:** 2015-08
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2015-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01073839

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01073839, "Adjuvant Cisplatin Plus Gemcitabine in Operable Cholangiocellular Carcinoma.". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT01073839. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*